The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Madeleine Duvic, Rakshandra Talpur, Xiao Ni et al. · Blood · 2006 · 1.1K citations · Full text

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

Richard Piekarz, Robin Frye, Maria L. Turner et al. · Journal of Clinical Oncology · 2009 · 728 citations · Full text

Immunology, Pathology, Pharmacotherapy +18

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Nagma Khan, Michael Jeffers, Sampath Kumar et al. · Biochemical Journal · 2007 · 707 citations · Full text

Histone Modifications, Class Ii, Specific Isoforms +20

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked <i>in vivo</i> antitumor activity against human tumors

Akiko Saito, Takashi Yamashita, Yukiyasu Mariko et al. · Proceedings of the National Academy of Sciences · 1999 · 696 citations · Full text

Histone deacetylase (HDAC) inhibitor activation of p21 ^WAF1 involves changes in promoter-associated proteins, including HDAC1

C. Gui, Lang Ngo, Weili Xu et al. · Proceedings of the National Academy of Sciences · 2004 · 549 citations · Full text

Histone Modifications, Epigenetic Change, Genetics +25